Acquired Company

Petra Acquisition, Inc. completed its business combination with Revelation Biosciences on January 10, 2022, after which the combined company traded on Nasdaq as Revelation Biosciences, Inc. under the ticker REVB.

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California. Show more

Location: 4660 La Jolla Village Drive, San Diego, CA, 92122, United States | Website: https://www.revbiosciences.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

5.622M

52 Wk Range

$0.76 - $20.16

Previous Close

$0.90

Open

$0.93

Volume

76,864

Day Range

$0.90 - $0.96

Enterprise Value

-7.086M

Cash

12.71M

Avg Qtr Burn

-2.513M

Insider Ownership

25.36%

Institutional Own.

11.90%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Gemini (IV) Details Stage 3-4 Chronic Kidney Disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.